title: Late termination of pregnancy and foetal reduction for foetal anomaly.
abstract: Late termination of pregnancy is a relatively rare procedure accounting for approximately 1% of all registered terminations in England and Wales; however, with improving detection rates for foetal anomalies, this number is increasing. Surgical dilation and evacuation (D&E) appears to be a safe and cost-effective procedure as long as the clinical expertise exists to provide this service. Medical termination appears equally safe and is best undertaken with the combined use of mifepristone and misoprostol. Foeticide, when required, should be performed from 22 weeks' gestation using strong KCl administered either by cardiocentesis or by cordocentesis. All women should be offered a post-mortem and any other appropriate investigation to allow accurate counselling regarding future pregnancies. The issue of late selective foetal reduction for foetal abnormality is complicated by the need to balance the risks to the healthy co-twin of expectant management versus selective termination.
authors.affiliation: St. Georges University of London, Cranmer Terrace, UK.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Napolitano
authors.forename: Basky
authors.initials: B
authors.lastname: Thilaganathan
mesh_terms: D000019:Abortifacient Agents / Q000008:administration & dosage*; D000282:Administration, Intravaginal; D000284:Administration, Oral; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage*; D016595:Misoprostol / Q000008:administration & dosage*; D011247:Pregnancy; D018607:Pregnancy Reduction, Multifetal / Q000379:methods*; D011262:Pregnancy Trimester, Second; D006113:United Kingdom; D014619:Vacuum Curettage / Q000379:methods*
chemical_list: D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone